IP Library Granted Patent US 11,672,857
Granted Patent B2
US 11,672,857 · App. 16/760,389 · Granted Jun 13, 2023

Compositions and methods for a multi-adjuvant only approach to immunoprophylaxis for preventing infections

Inventors: Brad Spellberg (Los Angeles, CA); Travis Nielsen (Los Angeles, CA); Brian Luna (Los Angeles, CA)
Assignee: UNIVERSITY OF SOUTHERN CALIFORNIA
A61K39/39A61K35/66A61K36/06A61K39/025A61K39/0258A61K39/0266A61K39/085A61K39/104A61K39/1045A61K2039/545A61K2039/55505A61K2039/55572A61K2039/55583A61K2039/58
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,672,857
App. No.
16/760,389
Granted
Jun 13, 2023
Kind
B2
Abstract

This disclosure provides a new vaccine composition and methods for its use. The composition contains an effective amount of each of: an aluminum hydroxide, a mono-phosphoryl lipid (MPL), and a whole glucan particles (WGP) but no an antigen that raises an immune response against a bacterial or fungal infection.

Claims (10)

1. A composition consisting essentially of an effective amount of each of aluminum hydroxide, mono-phosphoryl lipid (MPL), and whole glucan particles (WGP) with the proviso that the composition does not comprise an antigen effective to induce an immune response against a fungus or a bacterium.

2. A composition consisting essentially of an effective amount of each of aluminum hydroxide, mono-phosphoryl lipid (MPL), whole glucan particles (WGP), and mannan with the proviso that the composition does not comprise an antigen effective to induce an immune response against a fungus or a bacterium.

3. The composition of claim 1 , wherein the effective amount of the aluminum hydroxide is from 0.1 to 10 mg/ml and the effective amount of the MPL is from 0.1 to 10 mg/ml, and are combined in a ratio of from 1:1 to 1:20 for the aluminum hydroxide and the MPL to the WGP.

4. The composition of claim 2 , wherein the effective amount of the aluminum hydroxide is from 0.1 to 10 mg/ml and the effective amount of the MPL is from 0.1 to 10 mg/ml of the MPL, and are combined in a ratio of from 1:1 to 1:20 for the aluminum hydroxide and the MPL to the WGP, and wherein the effective amount of the mannan is from 0.01 mg/ml to 1 mg/ml.

5. The composition of claim 2 , wherein the effective amount of the mannan is from 0.01 mg/ml to 1 mg/ml.

6. A kit comprising the composition of claim 1 or claim 2 and instructions for use.

7. A method to augment innate immunity against a bacterium or a fungus in a mammalian subject comprising administering to the subject an effective amount of the composition of claim 1 or claim 2 .

8. The method of claim 7 , wherein the bacterium is selected from S. aureus, A. baumannii, K. pneumoniae, P. aeruginosa, E. coli, Enterobacter spp., Serratia, Stenotrophomonas , and the fungus is Candida spp.

9. The method of claim 7 , wherein the subject is at risk of a bacterial infection or a fungal infection.

10. The method of claim 7 , wherein the subject is infected with the bacterium or the fungus.

Assignments (2)
CONFIRMATORY LICENSE Recorded Jul 31, 2024
From: UNIVERSITY OF SOUTHERN CALIFORNIA
To: NATIONAL INSTITUTES OF HEALTH
Reel/Frame 068218/0726 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 29, 2020
From: SPELLBERG, BRAD; NIELSEN, TRAVIS; LUNA, BRIAN
To: UNIVERSITY OF SOUTHERN CALIFORNIA
Reel/Frame 052530/0290 →
Continuity (2)
Provisional Application 62578848 · Oct 30, 2017
Related Publication 20200353075A1 · Nov 12, 2020